TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Key Highlights
- ➤TEZSPIRE achieved week-24 histologic remission in 64.8% and 68.9% of patients versus 3.5% placebo
- ➤Week-24 dysphagia scores fell 18.8 and 22.0 points versus 14.7 points for placebo
- ➤Week-52 histologic remission reached 67.8% and 63.3% versus 5.4% placebo
- ➤Week-52 total endoscopic remission reached 34.4% and 29.5% versus 4.1% placebo
- ➤Amgen and AstraZeneca reported positive Phase 3 CROSSING results in eosinophilic esophagitis
Expert Statements
Jay Bradner, Executive vice president of Research and Development, Artificial Intelligence and Data at Amgen
“A new treatment approach is needed for people living with eosinophilic esophagitis, half of whom continue to experience uncontrolled symptoms despite standard treatment.”
Jay Bradner, Executive vice president of Research and Development, Artificial Intelligence and Data at Amgen
“We're pleased with the statistically significant and clinically meaningful, sustained improvements seen in CROSSING.”
Jay Bradner, Executive vice president of Research and Development, Artificial Intelligence and Data at Amgen
“As we continue to study TEZSPIRE across epithelial-driven inflammatory diseases, our focus remains on translating the science behind TSLP inhibition into meaningful outcomes for patients.”
Evan Dellon, Professor of medicine and adjunct professor of epidemiology at the University of North Carolina School of Medicine, and primary investigator in the trial
“The prevalence of eosinophilic esophagitis is on the rise and has become one of the fastest-growing chronic gastrointestinal conditions we see in the clinic.”
Evan Dellon, Professor of medicine and adjunct professor of epidemiology at the University of North Carolina School of Medicine, and primary investigator in the trial
“This disease can severely impede a person’s ability to eat and swallow, with many patients experiencing near-daily burden from the risk of food becoming stuck during meals.”
Evan Dellon, Professor of medicine and adjunct professor of epidemiology at the University of North Carolina School of Medicine, and primary investigator in the trial
“The CROSSING data suggest that tezepelumab, dosed once every four weeks, would be an important new treatment option to address key treatment goals in EoE across symptomatic, histologic and endoscopic outcomes.”
Arjan Bredenoord, Gastroenterologist and professor at the Amsterdam University Medical Center, and primary investigator in the trial
“The CROSSING trial results are compelling because they show consistent, lasting improvements across three key measures of eosinophilic esophagitis — histologic remission, frequency and severity of dysphagia, and endoscopic remission — sustained through 52 weeks.”
Arjan Bredenoord, Gastroenterologist and professor at the Amsterdam University Medical Center, and primary investigator in the trial
“Importantly, these meaningful results were seen even in patients who were allowed to remain on their stable background therapy.”
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS PR Newswire
Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52
Get started
Create a free account to read the full story.